ArticleFrontiers in medicine2025
Lichen sclerosus and the association with subsequent psychiatric disorders.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immunological aspects and quality of life among patients with lichen sclerosus.Skin health and disease · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lichen sclerosus (LS) is an acquired, non-communicable, chronic inflammatory disease that predominantly affects the genital area and may lead to substantial impairment in quality of life. While some studies reported elevated rates of depression and anxiety among patients with LS, the available evidence is limited by often small sample sizes, cross-sectional designs, narrow matching, and limited consideration of sex- or race-disparities. Moreover, the risk of a broader spectrum of psychiatric disorders remains insufficiently characterized. Objective: To evaluate the risk of a larger spectrum of psychiatric disorders following a diagnosis of LS in a retrospective cohort study. Methods: The US Collaborative Network of TriNetX was used to create a propensity-score-matched cohort of individuals with LS and non-LS controls ( Results: Within 5 years, 3.92% of patients with LS as opposed to 3.43% of controls were subsequently diagnosed with a depressive episode (HR 1.31, CI 1.22-1.40, Conclusion: Patients with LS are at a moderately increased risk of depression and stress-related psychiatric disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.